Emerging Infectious Diseases (Sep 2022)

Longitudinal SARS-CoV-2 Nucleocapsid Antibody Kinetics, Seroreversion, and Implications for Seroepidemiologic Studies

  • Michael Loesche,
  • Elizabeth W. Karlson,
  • Opeyemi Talabi,
  • Guohai Zhou,
  • Natalie Boutin,
  • Rachel Atchley,
  • Gideon Loevinsohn,
  • Jun Bai Park Chang,
  • Mohammad A. Hasdianda,
  • Adetoun Okenla,
  • Elizabeth Sampson,
  • Haley Schram,
  • Karen Magsipoc,
  • Kirsten Goodman,
  • Lauren Donahue,
  • Maureen MacGowan,
  • Lewis A. Novack,
  • Petr Jarolim,
  • Lindsey R. Baden,
  • Eric J. Nilles

DOI
https://doi.org/10.3201/eid2809.220729
Journal volume & issue
Vol. 28, no. 9
pp. 1859 – 1862

Abstract

Read online

Given widespread use of spike antibody in generating coronavirus disease vaccines, SARS-CoV-2 nucleocapsid antibodies are increasingly used to indicate previous infection in serologic surveys. However, longitudinal kinetics and seroreversion are poorly defined. We found substantial seroreversion of nucleocapsid total immunoglobulin, underscoring the need to account for seroreversion in seroepidemiologic studies.

Keywords